Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma

We analyzed 186 patients with lymphoma who received allogeneic stem cell transplant (ASCT) with fludarabine-melphalan (FM) conditioning and different donors [25 haploidentical (HD), 98 matched unrelated (MUD), and 63 matched related (MRD)] at our institution between 09/2009-01/2018. Patients receive...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Biol Blood Marrow Transplant
Autores principales: Saini, Neeraj Y., Saliba, Rima M., Rondon, Gabriela, Maadani, Farzaneh, Popat, Uday, Hosing, Chitra M., Betul, Oran, Bashir, Qaiser, Olson, Amanda, Nieto, Yago, Alousi, Amin, Kebriaei, Partow, Srour, Samer, Mehta, Rohtesh, Anderlini, Paolo, Shpall, Elizabeth J., Qazilbash, Muzaffar H., Khouri, Issa F., Fayad, Luis, Lee, Hun, Fowler, Nathan, Parmar, Simrit, Westin, Jason, Hagemeister, Fredrick, Champlin, Richard E., Ciurea, Stefan O.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265611/
https://ncbi.nlm.nih.gov/pubmed/30763728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.02.002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares